Home › Alzheimer's Disease › New Jersey
Alzheimer's Disease clinical trials in New Jersey
25 studies for Alzheimer's Disease are looking for participants at sites in New Jersey.
Cities in New Jersey
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Clinical Site, West Long Branch
RecruitingPhase 2
Ages 55 to 90 · All sexes · Updated Sep 30, 2026 · NCT06887192A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Bio Behavioral Health, Toms River
RecruitingPhase 2
Ages 55 and older · All sexes · Updated Sep 29, 2026 · NCT06540833A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Local Institution - 1664, Princeton
RecruitingPhase 3
Ages 55 to 90 · All sexes · Updated Sep 28, 2026 · NCT06937229A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
- The Cognitive and Research Center of New Jersey - Springfield- Site Number : 8400005, Springfield
RecruitingPhase 2
Ages 55 to 85 · All sexes · Updated Sep 22, 2026 · NCT07688213A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Advanced Memory Research Institute - CenExel - PPDS, Toms River
RecruitingPhase 3
Ages 55 to 90 · All sexes · Updated Sep 22, 2026 · NCT06585787Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons
- Kessler Foundation, East Hanover
Recruiting
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05048966Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
- CenExel Research - Toms River, Toms River
RecruitingPhase 2
Ages 55 to 80 · All sexes · Updated Sep 21, 2026 · NCT06847321Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- The Cognitive and Research Center of New Jersey, Ridgewood
- The Cognitive and Research Center of New Jersey, Springfield
RecruitingPhase 3
Ages 50 to 90 · All sexes · Updated Sep 21, 2026 · NCT07177352Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
- Hackensack Medical Center, Hackensack
Recruiting
Ages 50 to 100 · All sexes · Updated Sep 17, 2026 · NCT05295615A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- The Cognitive and Research Center of New Jersey, Springfield
- Advanced Clinical Institute, West Long Branch
RecruitingPhase 3
Ages 60 to 85 · All sexes · Updated Sep 17, 2026 · NCT06976203A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Local Institution - 2650, Toms River
RecruitingPhase 3
Ages 55 to 90 · All sexes · Updated Sep 16, 2026 · NCT07011745A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
- Eisai Trial Site #1, Nutley
RecruitingObservational study
All ages · All sexes · Updated Sep 16, 2026 · NCT07821658A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Global Medical Institutes LLC; Princeton Medical Institute, Princeton
RecruitingPhase 3
Ages 55 to 90 · All sexes · Updated Sep 16, 2026 · NCT07011732Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Local Institution - 0059, Livingston
- Local Institution - 0081, Toms River
RecruitingPhase 2
Ages 55 to 90 · All sexes · Updated Sep 1, 2026 · NCT06808984A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
- The Cognitive and Research Center of New Jersey - Ridgewood ( Site 1064), Ridgewood
- The Cognitive and Research Center of NJ ( Site 1057), Springfield
- CenExel- AMRI ( Site 1018), Toms River
RecruitingPhase 2
Ages 50 to 85 · All sexes · Updated Aug 26, 2026 · NCT07033494A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- CenExel AMRI, Toms River
RecruitingPhase 1
Ages 50 to 85 · All sexes · Updated Aug 24, 2026 · NCT06297590A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Advanced Memory Research Institute of New Jersey, Toms River
RecruitingPhase 3
Ages 60 to 85 · All sexes · Updated Aug 20, 2026 · NCT06976216Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Rutgers-Robert Wood Johnson Medical School, New Brunswick
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 4, 2026 · NCT06563895A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- The Cognitive and Research Center of New Jersey, Springfield
RecruitingPhase 3
Ages 55 and older · All sexes · Updated Jul 7, 2026 · NCT07602582A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
- CenExel-HRI, Marlton
RecruitingPhase 1Healthy volunteers welcome
Ages 45 to 85 · All sexes · Updated Jun 4, 2026 · NCT06657768A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
- Eisai Trial Site #1, Nutley
RecruitingObservational study
Ages 19 and older · All sexes · Updated Apr 21, 2026 · NCT06810960Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
- Nuclear Imaging Institute, Englewood
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Apr 13, 2026 · NCT07012993Exercise to Improve Brain Health in Older African Americans
- Rutgers, The State University of New Jersey - Newark campus, Newark
RecruitingPhase 2Healthy volunteers welcome
Ages 60 and older · All sexes · Updated Feb 20, 2026 · NCT05597124ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
- Rutgers - Institute for Health, New Brunswick
RecruitingPhase 2Healthy volunteers welcome
Ages 60 and older · All sexes · Updated Feb 6, 2026 · NCT07392723Open-label Extension Study in Participants With Early Alzheimer's Disease
- GSK Investigational Site, Toms River
RecruitingPhase 2
Ages 50 to 85 · All sexes · Updated Feb 2, 2026 · NCT07105709From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.